S-1或吉西他滨辅助治疗切除的胰腺癌：基于JASPAC-01试验的成本效益分析数据集

数据集获取（Figshare）

• 源站标题：S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial
• DOI：10.6084/m9.figshare.9962705.v1
• 发布日期：2019-10-10
• 文件数：3 个
• 文件总体积：214.97 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/S-1_or_gemcitabine_adjuvant_therapy_in_resected_pancreatic_cancer_a_cost-effectiveness_analysis_based_on_the_JASPAC-01_trial/9962705

命令行下载

curl -L -o "Supplementary Figure 1.tif" "https://ndownloader.figshare.com/files/17946371"
curl -L -o "Supplementary Figure 2.tif" "https://ndownloader.figshare.com/files/17946374"
curl -L -o "Supplementary Figure 3.tif" "https://ndownloader.figshare.com/files/17946377"

文件清单

• Supplementary Figure 1.tif（84.65 KB）
• Supplementary Figure 2.tif（52.28 KB）
• Supplementary Figure 3.tif（78.03 KB）

文件总体积 214.97 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

This study aimed to investigate the cost-effectiveness of adjuvant treatments in resected pancreatic cancer.
A Markov model was developed to mimic the disease process of postoperative pancreatic cancer, encompassing three health states (relapse-free survival, recurrent disease, and death). Health outcomes and utility scores were derived from the phase III trial and available literature. Cost data were calculated using standard fee data from the West China Hospital for 2017. One-way sensitivity analyses and probabilistic sensitivity analyses were developed to explore model uncertainty.
Treatment with S-1 was estimated to yield 1.61 quality-adjusted life-years (QALYs) at a cost of $25,696, whereas treatment with gemcitabine yielded 1.27 QALYs at a cost of $28,930. The incremental cost-effectiveness ratio of S-1 versus gemcitabine was $-9,490 per QALY. Based on the willingness-to-pay threshold of $25,841 per QALY, the net monetary benefit (NMB) was $15,786 for S-1 and $3,727 for gemcitabine, generating the incremental NMB of $12,059. A probabilistic sensitivity analysis revealed that the probabilities of S-1 and gemcitabine being cost-effective were 92% and 8%, respectively. Results were robust to changes in parameters.
Adjuvant therapy using S-1 is a cost-effective alternative compared to gemcitabine in patients with postoperative pancreatic cancer from the Chinese societal perspective.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.9962705.v1（source: https://tandf.figshare.com/articles/dataset/S-1_or_gemcitabine_adjuvant_therapy_in_resected_pancreatic_cancer_a_cost-effectiveness_analysis_based_on_the_JASPAC-01_trial/9962705）。